

Reading Materials

General Information on Pharmacogenomics

- ✍ Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. *N Engl J Med* 2003;348(6):538-49.
- ✍ Guttmacher A. E., Collins F. S., Carmona R. H. The family history – more important than ever. *N Engl J Med* 2004; 351:2333-2336.
- ✍ Hall AM, Wilkins MR. Warfarin: a case history in pharmacogenetics. *Heart* 2005;91(5):563-4.
- ✍ Hodgson J, Marshall A. Pharmacogenomics: will the regulators approve? *Nat Biotechnol* 1998;16(3):243-6.
- ✍ Noah L. The coming pharmacogenomics revolution: tailoring drugs to fit patients' genetic profiles. *Jurimetrics Journal* 2002;43(Fall):1-28.
- ✍ Weinshilboum R. Inheritance and drug response. *N Engl J Med* 2003;348(6):529-37.
- ✍ Wilkinson GR. Drug metabolism and variability among patients in drug response. *N Engl J Med* 2005;352(21):2211-21.
- ✍ Human Genome Project Information:
http://www.ornl.gov/sci/techresources/Human_Genome/medicine/pharma.shtml

Research on Population Differences in Drug Metabolism

- ✍ Chen K, Wang R, Wen SY, Li J, Wang SQ. Relationship of P450 2C9 genetic polymorphisms in Chinese and the pharmacokinetics of tolbutamide. *J Clin Pharm Ther* 2005;30(3):241-9.
- ✍ Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M, Leeder JS. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. *Can J Physiol Pharmacol* 2001;79(10):841-7.
- ✍ Liou YJ, Wang YC, Bai YM, et al. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. *Neuropsychobiology* 2004;49(4):167-73.
- ✍ Yin OQ, Tomlinson B, Chow MS. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. *Clin Pharmacol Ther* 2005;78(4):370-7.

- ✍ Ji L, Pan S, Wu J, Marti-Jaun J, Hersberger M. Genetic polymorphisms of CYP2D6 in Chinese mainland. *Chin Med J (Engl)* 2002;115(12):1780-4.

Genomic Research in Psychiatry

- ✍ de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. *Psychosomatics* 2006;47(1):75-85.
- ✍ Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. *Mol Psychiatry* 2004;9(5):442-73.

Pharmacogenomic Testing

- ✍ Roche Diagnostics:
http://www.roche-diagnostics.com/products_services/amplichip_cyp450.html
- ✍ Tm Bioscience: <http://www.tmbioscience.com/productsmain.php>
- ✍ Specialty Laboratories: <http://www.specialtylabs.com/spotlight/amplichip.asp>
- ✍ PGXL Laboratories: <http://www.pgxl.com/clinician/>
- ✍ Genelex Corp: <http://www.healthanddna.com/professional/pharmacogenetics.html>
- ✍ Seryx, Signature Genetics:
<http://www.signaturegenetics.com/sgtiles/en/corporate/main.jsp?id=1>

Side Effects

- ✍ Lazarou *JAMA* (1998) 279:1200-1205.
- ✍ Zimmerman M, Chelminski I, Posternak MA. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. *Am J Psychiatry* 2005;162(7):1370-2.
- ✍ Cohen JS. Antidepressants: an avoidable and solvable controversy. *Ann Pharmacother* 2004;38(10):1743-6.
- ✍ Cohen JS. Why aren't lower, effective, OTC doses available earlier by prescription? *Ann Pharmacother* 2003;37(1):136-42.
- ✍ Cohen JS. Do standard doses of frequently prescribed drugs cause preventable adverse effects in women? *J Am Med Womens Assoc* 2002;57(2):105-10, 14.

✍ Cohen JS. Avoiding adverse reactions. Effective lower-dose drug therapies for older patients. *Geriatrics* 2000;55(2):54-6, 9-60, 3-4.